Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients

Tara M. Narowski, Kristin Raphel, Lily E. Adams, Jenny Huang, Nadja A. Vielot, Ramesh Jadi, Aravinda M. de Silva, Ralph S. Baric, John E. Lafleur, Lakshmanane Premkumar
doi: https://doi.org/10.1101/2021.06.19.449100
Tara M. Narowski
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristin Raphel
2Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lily E. Adams
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
3Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Huang
2Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadja A. Vielot
4Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramesh Jadi
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aravinda M. de Silva
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph S. Baric
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
3Department of Epidemiology, University of North Carolina at Chapel Hill School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. Lafleur
2Department Emergency Medicine, George Washington University School of Medicine, Washington, DC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Prem@med.unc.edu jlafleur@mfa.gwu.edu
Lakshmanane Premkumar
1Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Prem@med.unc.edu jlafleur@mfa.gwu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

With the advance of SARS-CoV-2 vaccines, the outlook for overcoming the global COVID-19 pandemic has improved. However, understanding of immunity and protection offered by the SARS-CoV-2 vaccines against circulating variants of concern (VOC) is rapidly evolving. We investigated the mRNA vaccine-induced antibody responses against the referent WIV04 (Wuhan) strain, circulating variants, and human endemic coronaviruses in 168 naïve and previously infected people at three-time points. Samples were collected prior to vaccination, after the first and after the second doses of one of the two available mRNA-based vaccines. After full vaccination, both naïve and previously infected participants developed comparable robust SARS-CoV-2 specific spike IgG levels, modest IgM and IgA binding antibodies, and varying degrees of HCoV cross-reactive antibodies. However, the strength and frequency of neutralizing antibodies produced in naïve people were significantly lower than in the previously infected group. We also found that 1/3rd of previously infected people had undetectable neutralizing antibodies after the first vaccine dose; 40% of this group developed neutralizing antibodies after the second dose. In all subjects neutralizing antibodies produced against the B.1.351 and P.1 variants were weaker than those produced against the reference and B.1.1.7 strains. Our findings provide support for future booster vaccinations modified to be active against the circulating variants.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 19, 2021.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients
Tara M. Narowski, Kristin Raphel, Lily E. Adams, Jenny Huang, Nadja A. Vielot, Ramesh Jadi, Aravinda M. de Silva, Ralph S. Baric, John E. Lafleur, Lakshmanane Premkumar
bioRxiv 2021.06.19.449100; doi: https://doi.org/10.1101/2021.06.19.449100
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients
Tara M. Narowski, Kristin Raphel, Lily E. Adams, Jenny Huang, Nadja A. Vielot, Ramesh Jadi, Aravinda M. de Silva, Ralph S. Baric, John E. Lafleur, Lakshmanane Premkumar
bioRxiv 2021.06.19.449100; doi: https://doi.org/10.1101/2021.06.19.449100

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4110)
  • Biochemistry (8813)
  • Bioengineering (6518)
  • Bioinformatics (23456)
  • Biophysics (11788)
  • Cancer Biology (9205)
  • Cell Biology (13318)
  • Clinical Trials (138)
  • Developmental Biology (7433)
  • Ecology (11407)
  • Epidemiology (2066)
  • Evolutionary Biology (15146)
  • Genetics (10433)
  • Genomics (14041)
  • Immunology (9169)
  • Microbiology (22152)
  • Molecular Biology (8808)
  • Neuroscience (47559)
  • Paleontology (350)
  • Pathology (1428)
  • Pharmacology and Toxicology (2491)
  • Physiology (3730)
  • Plant Biology (8079)
  • Scientific Communication and Education (1437)
  • Synthetic Biology (2220)
  • Systems Biology (6037)
  • Zoology (1252)